Rospatent Grants Vector Research Center Patents for Coronavirus Vaccine


The Russian Federal Service for Intellectual Property, commonly known as Rospatent, told Sputnik on Wednesday it had granted the Vector research center patents for its COVID-19 vaccine. Earlier in the day, it was announced that Vector had finished the clinical trials of its vaccine against coronavirus.

“The Research Center of Virology and Biotechnology Vector has received patents for its vaccine against COVID-19,” a Rospatent spokesperson said.

The vaccine contains synthetic peptide antigens or fragments of the virus. The vaccine based on these antigens provokes an immune response and contributes to the development of immunity against COVID-19.

“In total, we issued three patents for inventions, each of which contains a certain modified fragment of the virus,” the intellectual property watchdog explained.

Earlier in the day, the head of the national public health watchdog said that Russian research center Vector had completed the clinical trials of its vaccine against COVID-19.

Last week, the watchdog said that the vaccine, dubbed EpiVacCorona, would be registered by 15 October.

In August, Russian President Vladimir Putin announced the registration of the world’s first vaccine against the virus that causes COVID-19, which was developed by the country’s Gamaleya Research Institute.